Belzutifan VHL RCC HK Prospective Registry

Starting soon

Conditions studied: VHL - Von Hippel-Lindau Syndrome

In brief

This study aims to evaluate the Belzutifan's efficacy, drug safety, disease course, and the health-economic impact of the treatment to Von Hippel-Lindau (VHL) syndrome.

Key facts

Study ID

NCT07554508

Run by

Chinese University of Hong Kong

People needed

100

Starts

2026-05-01

Expected to finish

2029-03-31

Last updated by the study team

2026-05-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients (age 18 or above) with confirmed VHL-spectrum disease through clinical and/or genetic diagnosis.
• The patient decided to use Belzutifan for their treatment.

You may not qualify if…

• Tumour requiring immediate resection.
• Pregnancy or unwillingness to use contraception if of childbearing potential.
• Uncontrolled comorbidities (e.g., active infection, severe cardiopulmonary disease).

Where it is running

• Prince of Wales Hospital — Shatin, Hong Kong

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.